GSK joins pharma giants dropping anti-TIGIT drugs The news may come as a shock to the oncology field, as GSK and iTeos provided the first data for the GALAXIES Lung-201 study at the European ...

Mereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. The finance round was led by OrbiMed and comes almost exactly two years after Mereo ...

Tiragolumab is aimed at an immune cell protein called TIGIT, a drug target that was uncovered by scientists at Roche’s Genentech subsidiary. Researchers there have been studying TIGIT’s role ...

Belgium-based iTeos decided in May that with its TIGIT dreams in ruins, its best bet was to wind down operations, sell its assets and return as much of its $600 million-plus cash pile to investors ...

The TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research. Gain access to 1:1 time with leaders in TIGIT development, and take away tangible learnings with dedicated ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. The British Big ...

Cancer Immunotherapy Dominating TIGIT Clinical Trials Landscape With More Than 15 Drugs And 30 Trials Says Kuick ResearchDelhi, Nov. 26, 2021 (GLOBE NEWSWIRE) -- TIGIT Inhibitor Clinical Trials ...

Compugen: New Data Shows Potential Of Combining TIGIT, PVRIG In Treatment Of Multiple Myeloma March 09, 2022 — 07:29 am EST Written by RTTNews.com for RTTNews -> ...

Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a ...

Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of ...

TIGIT is expressed on T cells and serves as a brake to those T cells,” Freed-Pastor said. “When a TIGIT-positive T cell encounters any cell expressing high levels of CD155, it can essentially ...

The anti-TIGIT bispecific antibody AGEN-1777’s preclinical status didn’t stand in the way of Bristol Myers Squibb Co.’s whopper deal with Agenus Inc., which is collecting $200 million up front and as ...